Clinical trials: Metastatic Malignant Neoplasm to Brain
Breast Cancer
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Our hypothesis is that this study design, in which bevacizumab is added to one of six single agent chemotherapies with proven activity in metastatic breast cancer, will result in regression or stabilization of this disease in a…
- Trial name
- NCT00476827
- Testing
- Bevacizumab, Docetaxel, CPT-11
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Duke University
Brain Metastases
A Proof-of-principle Study of HBO-SRS for Brain Metastases
Patients with brain metastases who are candidates for treatment with stereotactic radiosurgery (SRS) are potential study participants.
- Trial name
- NCT01850563
- Testing
- Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Brain Tumor, Brain Metastases
Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study
This study will evaluate the rate of radiation necrosis following treatment with immune checkpoint inhibitor (ICI) treatment and radiation therapy in subjects with metastatic brain cancer.
- Conditions
- Brain Tumor, Brain Metastases, Brain Cancer
- Trial name
- RADREMI (NCT04047602)
- Testing
- Reduced Dose SRS
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Indiana University
Lung Cancer, Brain Metastases
Clinical Evaluation of the Treatment of Intellectual Metastases by Radiosurgery Gamma Knife by Means of a Support System by Mask.
the Mask fixation isn't a new solution for the immobilization of the patient's head and has been used in current practice for long years.
- Trial name
- Mask (NCT02732769)
- Testing
- GammaKnifePerfexion®, GammaKnifeIcon®, Efficast®
- Where
- France
- Volunteers
- 58 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Brain Metastases, Neurocognitive Deficit
MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets
Brain metastases are a source of much morbidity and mortality in adults with primary solid malignant tumors. With improvements in systemic therapy that prolong survival but have limited central nervous system penetration…
- Conditions
- Brain Metastases, Neurocognitive Deficit, White Matter Alterations, Radiation Exposure
- Trial name
- NCT04073966
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Brain Metastases, Radiotherapy Side Effect
GM1 Prophylaxis for WBRT Related Cognitive Dysfunction
To evaluate the efficacy and safety of GM1 for preventing cognitive impairment related to whole brain radiotherapy in breast cancer patients with brain metastases.
- Conditions
- Brain Metastases, Radiotherapy Side Effect, Cognitive Impairment, Gangliosidosis, GM1
- Trial name
- GLORY (NCT04395339)
- Testing
- Monosialotetrahexosyl ganglioside (GM1), Control
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Lung Cancer, Metastatic Cancer
WBRT & Erlotinib in Advanced NSCLC and Brain Metastases
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- TACTIC (NCT00554775)
- Testing
- erlotinib hydrochloride
- Where
- 7 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- University College, London
Breast Neoplasms
A Study of Local Therapy for the Treatment of Brain Metastases From HER2 Positive Breast Cancer
This study aims to show that brain metastases from Human Epidermal Growth Factor Receptor Type 2 (HER2) positive breast cancers are able to be controlled by local therapies, Stereotactic Radiosurgery (SRS) and/or Neurosurgery…
- Trial name
- Local HER-O (NCT02898727)
- Testing
- Local Therapy
- Where
- Australia
- Volunteers
- 25 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Cancer, Metastatic Cancer
Observation for Patients With Asymptomatic CNS Metastatic Disease
The purpose of this registry is to determine if select patients with CNS metastatic disease can be safely observed rather than treated.
- Trial name
- NCT02866981
- Testing
- Observation
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- The Cooper Health System
Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
This phase I trial studies the side effects and best dose of berzosertib (M6620 [VX-970]) when given together with whole brain radiation therapy in treating patients with non-small cell lung cancer, small cell lung cancer, or…
- Conditions
- Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT02589522
- Testing
- Berzosertib, Quality-of-Life Assessment, Therapeutic Conventional Surgery
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Metastatic Cancer
Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of carmustine followed by surgery in treating patients…
- Trial name
- NCT00009854
- Testing
- carmustine in ethanol, conventional surgery
- Where
- 2 sites in United States
- Sponsor
- Direct Therapeutics
Cancer
Breast Cancer With Over-expression of erbB2-BRAINSTORM
This retrospective cohort study aims to improve our understanding of the current paradigm for treatment of brain metastases in erbB2+ breast cancer patients in the Asia Pacific region.
- Trial name
- NCT01064349
- Testing
- Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer
- Where
- 10 sites in Philippines, Singapore and 1 more
- Volunteers
- 144 people
- Sponsor
- GlaxoSmithKline
NSCLC Stage IV, Brain Metastases
Genomic Study in Non-small Cell Lung Cancer Brain Metastasis
The investigators collected the data from the investigators' center between January 2011 and October 2020. The study included all non-small cell lung cancer patients with surgically excised brain metastasis.
- Trial name
- NCT04745715
- Testing
- craniectomy
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- National Cheng-Kung University Hospital
Breast Cancer, Metastatic Cancer
Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00875355
- Testing
- temozolomide, radiation therapy
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut Curie
Malignant Melanoma, BRAF V600 Mutation
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
This study evaluates the addition of stereotactic radiosurgery (SRS) to the combination of binimetinib + encorafenib + pembrolizumab in the treatment of BRAFⱽ⁶⁰⁰ mutation-positive melanoma with brain metastases (MBM).
- Conditions
- Malignant Melanoma, BRAF V600 Mutation, Brain Metastases
- Trial name
- BEPCOME-MB (NCT04074096)
- Testing
- Stereotaxic radiosurgery (SRS), Binimetinib Oral Tablet, Encorafenib Oral Capsule
- Where
- 21 sites in France
- Volunteers
- 10 people
- Sponsor
- UNICANCER
Neuroectodermal Tumor, Brain Metastases
Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases
Primary Objective: Determine the interindividual range and median of individual maximum tolerated doses of valproic acid administered as one time evening dose in conjunction with a dose oral etoposide (50 mg/m2/day for children…
- Conditions
- Neuroectodermal Tumor, Brain Metastases, Advanced Cancer
- Trial name
- NCT00513162
- Testing
- Valproate, Etoposide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Asymptomatic Brain Metastases, Driver Mutation Positive Non-small Cell Lung Cancer
Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Tyrosine Kinase Inhibitors (TKIs) especially higher generation TKI have higher CNS penetration rates and have shown favorable response rates in brain metastases.
- Trial name
- NCT05236946
- Testing
- Stereotactic radiosurgery/whole brain radiotherapy, Tyrosine kinase inhibitor
- Where
- India
- Volunteers
- 190 people
- Sponsor
- Tata Memorial Hospital
Brain Neoplasms, Neoplasm Metastasis
A Trial of Postoperative Whole Brain Radiation Therapy vs. Salvage Stereotactic Radiosurgery Therapy for Metastasis
The aim of this study is to evaluate non-inferiority of salvage stereotactic radiosurgery (SRS) in the patients who received surgical resection for brain metastases in comparison with postoperative whole brain radiation therapy…
- Trial name
- NCT00280475
- Testing
- Whole brain radiation therapy arm, Salvage stereotactic radiosurgery arm
- Where
- 21 sites in Japan
- Volunteers
- 270 people
- Sponsor
- Haruhiko Fukuda
Glioma, Brain Metastases
Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI
Standard Magnetic Resonance Imaging (MRI) is based on the excitation of hydrogen nuclei that are presents in water molecules, which abundance in human body allows for obtention of superior contrast.
- Trial name
- GlioCEST (NCT05464992)
- Testing
- Additional CEST sequences during PET/MRI exam
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Centre Paul Strauss
Glioblastoma, Glial Tumor
Evaluation of the CONVIVO System
The primary objective of this study is to evaluate the diagnostic performance of the CONVIVO confocal endomicroscope in discriminating between normal and abnormal tissue in vivo during brain tumor surgery.
- Conditions
- Glioblastoma, Glial Tumor, Brain Metastases, Meningioma
- Trial name
- NCT05139277
- Testing
- CONVIVO system, Conventional histologic evaluation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.